<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/viking-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MDMwNjEzMDYwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/viking-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MDMwNjEzMDYwNQ"/></p>
<p>维京治疗（NASDAQ：VKTX - 获取免费报告）的股票在周二的一份研究报告中被 HC Wainwright 的股票研究分析师重新确认为 “买入” 评级，据 Benzinga 报道。他们目前对这家生物技术公司的股票设定了 90.00 美元的价格目标。HC Wainwright 的价格目标显示，相较于股票之前的收盘价，有 45.75% 的潜在上涨空间。</p>
<p>获取 <strong>维京治疗</strong> 的警报：</p>
<ul>
<li>艾利·莉莉（Eli Lilly）因 GLP-1 减重现象而上涨</li>
</ul>
<p>其他几家股票研究分析公司最近也对该公司发表了评论。Stifel Nicolaus 在 3 月 15 日星期五的研究报告中重申了 “买入” 评级，并对维京治疗的股票设定了 80.00 美元的目标价。Maxim Group 在 3 月 15 日星期五的研究报告中重申了 “买入” 评级，并对维京治疗的股票设定了 120.00 美元的目标价。Truist Financial 在 5 月 16 日星期四的研究报告中重申了 “买入” 评级，并对维京治疗的股票设定了 120.00 美元的价格目标。William Blair 在 2 月 23 日星期五的研究报告中重申了对维京治疗的 “表现优异” 评级。最后，BTIG Research 将维京治疗的价格目标从 100.00 美元上调至 125.00 美元，并在 3 月 26 日星期二的研究报告中给予该股票 “买入” 评级。一位股票研究分析师对该股票进行了卖出评级，八家公司给予了买入评级，一家公司给予了强烈买入评级。根据 MarketBeat 的数据，维京治疗目前的共识评级为 “中度买入”，平均目标价为 112.38 美元。</p>
<p>获取我们关于维京治疗的最新报告</p>
<h2>维京治疗股票下跌 0.8%</h2>
<ul>
<li>Wegovy vs. Zepbound：GLP-1 药物之战谁将获胜？</li>
</ul>
<p>周二，纳斯达克：VKTX 的股票下跌了 0.52 美元，收于 61.75 美元。该公司的股票交易量为 1,115,532 股，相比其平均交易量 4,970,656 股有所下降。该公司的市值为 68.1 亿美元，市盈率为-67.17，贝塔系数为 1.05。该公司的 50 天移动平均价格为 71.44 美元，200 天移动平均价格为 46.58 美元。维京治疗的 52 周最低价为 8.28 美元，最高价为 99.41 美元。</p>
<p>维京治疗（NASDAQ：VKTX - 获取免费报告）上次发布财报是在 4 月 24 日星期三。这家生物技术公司报告的每股收益为（0.26）美元，超过了每股（0.27）美元的共识预期。在去年同期，该公司每股收益为（0.25）美元。分析师平均预测，维京治疗在本财年将实现-1.08 美元的每股收益。</p>
<h2>维京治疗内部交易</h2>
<ul>
<li>Altimmune 能否在现金流耗尽之前将其 GLP-1 药物推向市场？</li>
</ul>
<p>在其他维京治疗的消息中，首席财务官 Greg Zante 于 5 月 3 日星期五以每股 74.69 美元的均价出售了 66,756 股公司股票。该交易总价值为 4,986,005.64 美元。交易完成后，首席财务官现在直接持有公司股票 174,854 股，价值约 13,059,845.26 美元。该交易已在向 SEC 提交的法律文件中披露，可通过此链接访问。此外，首席运营官 Marianna Mancini 于 5 月 1 日星期三以每股 78.66 美元的均价出售了 281,425 股股票。该股票的总交易额为 22,136,890.50 美元。交易完成后，首席运营官现在直接持有公司股票 348,508 股，价值约 27,413,639.28 美元。该交易已在向 SEC 提交的法律文件中披露，可通过 SEC 网站访问。此外，首席财务官 Greg Zante 于 5 月 3 日星期五以每股 74.69 美元的均价出售了 66,756 股公司股票。该交易总价值为 4,986,005.64 美元。交易完成后，首席财务官持有公司股票 174,854 股，价值 13,059,845.26 美元。有关此次交易的披露可在此处找到。内部持有公司股票的比例为公司股份的 4.70%。</p>
<h2>维京治疗的机构交易</h2>
<p>机构投资者和对冲基金最近调整了他们对该公司的持股。Rafferty Asset Management LLC 在第 3 季度将其在维京治疗的持股增加了 63.6%。Rafferty Asset Management LLC 现在拥有 560,180 股这家生物技术公司的股票，价值 6,201,000 美元，比上一季度增加了 217,827 股。International Assets Investment Management LLC 在第 4 季度将其在维京治疗的持股增加了 1,557.6%。International Assets Investment Management LLC 现在拥有 371,604 股这家生物技术公司的股票，价值 6,916,000 美元，比上一季度增加了 349,186 股。Raymond James &amp; Associates 在第 4 季度将其在维京治疗的持股增加了 100.4%。Raymond James &amp; Associates 现在拥有 137,583 股这家生物技术公司的股票，价值 2,560,000 美元，比上一季度增加了 68,921 股。Vanguard Group Inc.在第 3 季度将其在维京治疗的持股增加了 3.4%。Vanguard Group Inc.现在拥有 5,284,352 股这家生物技术公司的股票，价值 58,498,000 美元，比上一季度增加了 171,995 股。最后，Aigen Investment Management LP 在第 3 季度购入了维京治疗的股份，价值 148,000 美元。目前，公司股份的 76.03% 由机构投资者持有。</p>
<h2>关于维京治疗（获取免费报告）</h2>
<p>Viking 治疗公司是一家临床阶段的生物制药公司，专注于开发治疗代谢和内分泌疾病的新型疗法。该公司的主力药物候选是 VK2809，一种口服可用的组织和受体亚型选择性激动剂，作用于甲状腺激素受体β（TRß），目前正在进行 IIb 期临床试验，用于治疗经活检确认的非酒精性脂肪肝病患者，以及 NAFLD。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们比 Viking 治疗更喜欢的股票</li>
<li>什么是股息？购买最佳股息股票</li>
<li>Birkenstock 看起来适合任何成长型投资组合</li>
<li>什么是富时 100 指数？</li>
<li>本季度最活跃的国会交易</li>
<li>期权交易 - 了解行权价</li>
<li>C3.ai 开始展现人工智能助推力加速</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 特别免费提供股票热表（来自 DTI）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTY0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTY0"/></p>
<h2>现在是否值得投资 1,000 美元购买 Viking 治疗股票？</h2>
<p>在考虑购买 Viking 治疗股票之前，您需要听到这个消息。</p>
<p>MarketBeat 追踪华尔街顶尖和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶尖分析师悄悄告诉客户现在购买的股票，让更广泛的市场注意到...而 Viking 治疗并不在名单上。</p>
<p>尽管 Viking 治疗目前在分析师中有 “买入” 评级，但顶尖分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Viking治疗

<p>维京治疗（NASDAQ:VKTX）收到了 HC Wainwright 的 “买入” 评级，目标股价为 90.00 美元。其他分析师也对这家生物技术公司给予了积极评价。维京治疗的 52 周最低股价为 8.28 美元，52 周最高股价为 99.41 美元。该公司的股票在上一个交易日收盘价为 61.75 美元，市值为 68.1 亿美元。内部人士一直在抛售该公司的股份</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/viking-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MDMwNjEzMDYwNQ" alt="" original-src="https://www.marketbeat.com/logos/viking-therapeutics-inc-logo-1200x675.png?v=20240306130605"/></p>
<p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report)'s stock had its &#34;buy&#34; rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $90.00 price objective on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 45.75% from the stock's previous close.</p>
<div class="lb-trans"><p>维京治疗（NASDAQ：VKTX - 获取免费报告）的股票在周二的一份研究报告中被 HC Wainwright 的股票研究分析师重新确认为 “买入” 评级，据 Benzinga 报道。他们目前对这家生物技术公司的股票设定了 90.00 美元的价格目标。HC Wainwright 的价格目标显示，相较于股票之前的收盘价，有 45.75% 的潜在上涨空间。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<ul>
<li>Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon</li>
</ul>
<div class="lb-trans"><p>获取 <strong>维京治疗</strong> 的警报：</p>
<ul>
<li>艾利·莉莉（Eli Lilly）因 GLP-1 减重现象而上涨</li>
</ul>
</div><p>Several other equities research analysts have also recently commented on the company. Stifel Nicolaus restated a &#34;buy&#34; rating and issued a $80.00 target price on shares of Viking Therapeutics in a research note on Friday, March 15th. Maxim Group restated a &#34;buy&#34; rating and issued a $120.00 target price on shares of Viking Therapeutics in a research note on Friday, March 15th. Truist Financial reiterated a &#34;buy&#34; rating and set a $120.00 price objective on shares of Viking Therapeutics in a research note on Thursday, May 16th. William Blair reiterated an &#34;outperform&#34; rating on shares of Viking Therapeutics in a research note on Friday, February 23rd. Finally, BTIG Research upped their price objective on Viking Therapeutics from $100.00 to $125.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Viking Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $112.38.</p>
<div class="lb-trans"><p>其他几家股票研究分析公司最近也对该公司发表了评论。Stifel Nicolaus 在 3 月 15 日星期五的研究报告中重申了 “买入” 评级，并对维京治疗的股票设定了 80.00 美元的目标价。Maxim Group 在 3 月 15 日星期五的研究报告中重申了 “买入” 评级，并对维京治疗的股票设定了 120.00 美元的目标价。Truist Financial 在 5 月 16 日星期四的研究报告中重申了 “买入” 评级，并对维京治疗的股票设定了 120.00 美元的价格目标。William Blair 在 2 月 23 日星期五的研究报告中重申了对维京治疗的 “表现优异” 评级。最后，BTIG Research 将维京治疗的价格目标从 100.00 美元上调至 125.00 美元，并在 3 月 26 日星期二的研究报告中给予该股票 “买入” 评级。一位股票研究分析师对该股票进行了卖出评级，八家公司给予了买入评级，一家公司给予了强烈买入评级。根据 MarketBeat 的数据，维京治疗目前的共识评级为 “中度买入”，平均目标价为 112.38 美元。</p>
</div><p><strong>Get Our Latest Report on Viking Therapeutics</strong></p>
<div class="lb-trans"><p>获取我们关于维京治疗的最新报告</p>
</div><h2>Viking Therapeutics Trading Down 0.8 %</h2>
<ul>
<li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li>
</ul>
<div class="lb-trans"><h2>维京治疗股票下跌 0.8%</h2>
<ul>
<li>Wegovy vs. Zepbound：GLP-1 药物之战谁将获胜？</li>
</ul>
</div><p>Shares of NASDAQ:VKTX traded down $0.52 during trading on Tuesday, hitting $61.75. 1,115,532 shares of the company's stock traded hands, compared to its average volume of 4,970,656. The company has a market cap of $6.81 billion, a price-to-earnings ratio of -67.17 and a beta of 1.05. The company has a 50-day moving average price of $71.44 and a 200-day moving average price of $46.58. Viking Therapeutics has a 52 week low of $8.28 and a 52 week high of $99.41.</p>
<div class="lb-trans"><p>周二，纳斯达克：VKTX 的股票下跌了 0.52 美元，收于 61.75 美元。该公司的股票交易量为 1,115,532 股，相比其平均交易量 4,970,656 股有所下降。该公司的市值为 68.1 亿美元，市盈率为-67.17，贝塔系数为 1.05。该公司的 50 天移动平均价格为 71.44 美元，200 天移动平均价格为 46.58 美元。维京治疗的 52 周最低价为 8.28 美元，最高价为 99.41 美元。</p>
</div><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. During the same period in the prior year, the firm posted ($0.25) earnings per share. On average, analysts predict that Viking Therapeutics will post -1.08 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>维京治疗（NASDAQ：VKTX - 获取免费报告）上次发布财报是在 4 月 24 日星期三。这家生物技术公司报告的每股收益为（0.26）美元，超过了每股（0.27）美元的共识预期。在去年同期，该公司每股收益为（0.25）美元。分析师平均预测，维京治疗在本财年将实现-1.08 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Viking Therapeutics</h2>
<ul>
<li>Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?</li>
</ul>
<div class="lb-trans"><h2>维京治疗内部交易</h2>
<ul>
<li>Altimmune 能否在现金流耗尽之前将其 GLP-1 药物推向市场？</li>
</ul>
</div><p>In other Viking Therapeutics news, CFO Greg Zante sold 66,756 shares of the company's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $74.69, for a total value of $4,986,005.64. Following the transaction, the chief financial officer now directly owns 174,854 shares of the company's stock, valued at approximately $13,059,845.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, COO Marianna Mancini sold 281,425 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the sale, the chief operating officer now directly owns 348,508 shares of the company's stock, valued at approximately $27,413,639.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Greg Zante sold 66,756 shares of the company's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $74.69, for a total value of $4,986,005.64. Following the sale, the chief financial officer now owns 174,854 shares of the company's stock, valued at $13,059,845.26. The disclosure for this sale can be found here. Insiders own 4.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他维京治疗的消息中，首席财务官 Greg Zante 于 5 月 3 日星期五以每股 74.69 美元的均价出售了 66,756 股公司股票。该交易总价值为 4,986,005.64 美元。交易完成后，首席财务官现在直接持有公司股票 174,854 股，价值约 13,059,845.26 美元。该交易已在向 SEC 提交的法律文件中披露，可通过此链接访问。此外，首席运营官 Marianna Mancini 于 5 月 1 日星期三以每股 78.66 美元的均价出售了 281,425 股股票。该股票的总交易额为 22,136,890.50 美元。交易完成后，首席运营官现在直接持有公司股票 348,508 股，价值约 27,413,639.28 美元。该交易已在向 SEC 提交的法律文件中披露，可通过 SEC 网站访问。此外，首席财务官 Greg Zante 于 5 月 3 日星期五以每股 74.69 美元的均价出售了 66,756 股公司股票。该交易总价值为 4,986,005.64 美元。交易完成后，首席财务官持有公司股票 174,854 股，价值 13,059,845.26 美元。有关此次交易的披露可在此处找到。内部持有公司股票的比例为公司股份的 4.70%。</p>
</div><h2>Institutional Trading of Viking Therapeutics</h2>
<div class="lb-trans"><h2>维京治疗的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the business. Rafferty Asset Management LLC lifted its position in shares of Viking Therapeutics by 63.6% during the 3rd quarter. Rafferty Asset Management LLC now owns 560,180 shares of the biotechnology company's stock worth $6,201,000 after buying an additional 217,827 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Viking Therapeutics by 1,557.6% during the 4th quarter. International Assets Investment Management LLC now owns 371,604 shares of the biotechnology company's stock worth $6,916,000 after buying an additional 349,186 shares during the last quarter. Raymond James &amp; Associates lifted its position in shares of Viking Therapeutics by 100.4% during the 4th quarter. Raymond James &amp; Associates now owns 137,583 shares of the biotechnology company's stock worth $2,560,000 after buying an additional 68,921 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Viking Therapeutics by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 5,284,352 shares of the biotechnology company's stock worth $58,498,000 after buying an additional 171,995 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Viking Therapeutics during the 3rd quarter worth $148,000. 76.03% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了他们对该公司的持股。Rafferty Asset Management LLC 在第 3 季度将其在维京治疗的持股增加了 63.6%。Rafferty Asset Management LLC 现在拥有 560,180 股这家生物技术公司的股票，价值 6,201,000 美元，比上一季度增加了 217,827 股。International Assets Investment Management LLC 在第 4 季度将其在维京治疗的持股增加了 1,557.6%。International Assets Investment Management LLC 现在拥有 371,604 股这家生物技术公司的股票，价值 6,916,000 美元，比上一季度增加了 349,186 股。Raymond James &amp; Associates 在第 4 季度将其在维京治疗的持股增加了 100.4%。Raymond James &amp; Associates 现在拥有 137,583 股这家生物技术公司的股票，价值 2,560,000 美元，比上一季度增加了 68,921 股。Vanguard Group Inc.在第 3 季度将其在维京治疗的持股增加了 3.4%。Vanguard Group Inc.现在拥有 5,284,352 股这家生物技术公司的股票，价值 58,498,000 美元，比上一季度增加了 171,995 股。最后，Aigen Investment Management LP 在第 3 季度购入了维京治疗的股份，价值 148,000 美元。目前，公司股份的 76.03% 由机构投资者持有。</p>
</div><h2>About Viking Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>关于维京治疗（获取免费报告）</h2>
</div><p>Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.</p>
<div class="lb-trans"><p>Viking 治疗公司是一家临床阶段的生物制药公司，专注于开发治疗代谢和内分泌疾病的新型疗法。该公司的主力药物候选是 VK2809，一种口服可用的组织和受体亚型选择性激动剂，作用于甲状腺激素受体β（TRß），目前正在进行 IIb 期临床试验，用于治疗经活检确认的非酒精性脂肪肝病患者，以及 NAFLD。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Viking Therapeutics</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Birkenstock Looks Like a Fit in Any Growth-Oriented Portfolio</li>
<li>What is the FTSE 100 index?</li>
<li>These Are the Most Active Congressional Trades This Quarter</li>
<li>Options Trading - Understanding Strike Price</li>
<li>C3.ai is Starting to Show AI Tailwinds Accelerating</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们比 Viking 治疗更喜欢的股票</li>
<li>什么是股息？购买最佳股息股票</li>
<li>Birkenstock 看起来适合任何成长型投资组合</li>
<li>什么是富时 100 指数？</li>
<li>本季度最活跃的国会交易</li>
<li>期权交易 - 了解行权价</li>
<li>C3.ai 开始展现人工智能助推力加速</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=VKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Special FREE offer on stock hotsheets (From DTI)(Ad)</p>
<div class="lb-trans"><p>→ 特别免费提供股票热表（来自 DTI）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTY0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8164&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Viking Therapeutics right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买 Viking 治疗股票？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Viking 治疗股票之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶尖和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶尖分析师悄悄告诉客户现在购买的股票，让更广泛的市场注意到...而 Viking 治疗并不在名单上。</p>
</div><p>While Viking Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Viking 治疗目前在分析师中有 “买入” 评级，但顶尖分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Viking 治疗（NASDAQ 代码：VKTX）获得 HC Wainwright 的 “买入” 评级